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Purpose: There is a lack of guidance in referring patients to the clinical pharmacist for diabetes 
management, which likely results in patients missing out on this beneficial service. It would be 
useful to know which patients and specific clinical interventions are most likely to show benefit 
from pharmacy services. To our knowledge, only one study has assessed patient predictors of 
response to diabetes care provided by a clinical pharmacist, which was limited to baseline 
variables. Therefore, the primary objective was to describe clinical responses to pharmacist-led 
diabetes care and to identify baseline and interventional variables that are independently 
predictive of clinical response. 
Methods: This was a retrospective cohort study using patient data from two health systems in 
San Antonio, Texas. Included patients were ≥18 years old with a referral to the pharmacist for 
Type 2 Diabetes management. Patients were followed for up to 6 months and data were collected 
at baseline, during follow-up, and at the end of the study. Clinical response was defined as a 
reduction in the A1C from baseline by ≥1% or meeting the documented A1C goal. Non-
 vii 
responders failed to meet these A1C goals. Variables with P<0.20 on bivariate analysis were 
included in the multiple variable logistic regression model to determine predictors of response. 
Results: A total of 180 patients were included. Overall, patients were predominantly female 
(63%) and obese (58%) with a disease duration ≥10 years (67%). The median (IQR) change in 
A1C from baseline for responders and non-responders was -2.2% (-3.7 to 1.3) and 0.4% (-0.4 to 
1.05) (P<0.001), respectively. Sixty-six percent of patients were considered responders. 
Significant predictors of response included baseline A1C (OR 1.41; 95% CI 1.08-1.85), number 
of completed visits with both the physician (OR 0.69; 95% CI 0.49-0.96) and the pharmacist (OR 
1.65; 95% CI 1.03-2.64), and medication optimization (OR 10.7; 95% CI 1.04-109.9). 
Conclusion: Pharmacists are effective in diabetes management. Specifically, more visits with 
the pharmacist and utilizing medication optimization are especially helpful in lowering the A1C. 
Higher baseline A1C values are also predictive of response and should be incorporated into new 
protocols for pharmacist management of diabetes. 
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Chapter One: Current Healthcare Landscape in the United States 
 CHRONIC DISEASE BURDEN AND POPULATION CHALLENGES 
Chronic diseases are highly prevalent in the United States (U.S.) today. A chronic disease 
is one that lasts one year or more, limits functional capacity, and requires ongoing medical 
treatment.1 Common examples include cancer, heart disease, diabetes mellitus, and chronic 
kidney disease. In 2014, 6 in 10 Americans had at least one chronic disease and 4 in 10 had more 
than one.1 In fact, the leading causes of death in the U.S. in 2017 were heart disease and cancer 
with 647,457 and 599,108 deaths, respectively.2 Notably, diabetes mellitus as a cause of death 
has more than doubled from 34,583 deaths in 1980 to 83,564 deaths in 2017.3 Multiple chronic 
diseases contribute to increased healthcare burden and resource utilization. For example, patients 
with five or more conditions spend about 14 times more on healthcare expenditures per year 
compared to patients with no chronic diseases. This includes prescription medications, hospital 
stays, and emergency room visits, among other costs. With a significant portion of the population 
affected and many healthcare dollars spent on chronic diseases, more emphasis should be placed 
on their management and prevention. 
Chronic diseases disproportionately affect older adults. The proportion of multiple 
chronic conditions in those 65 years and older (81%) is substantially higher compared to those 
45-64 years (50%) and 18-44 years (18%).1,4,5 Thus, an aging population exacerbates the high 
burden of chronic disease on the U.S. healthcare system. Adults ≥65 years old are expected to 
more than double in population from 46 million to 98 million by 2060.6 In comparison, the 
population <18 years old is only expected to grow 3% during the same timeframe. This growth 
will likely lead to increased utilization of healthcare resources, as well as place a strain on the 
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resources that support this population. The elderly support ratio, which is the number of 
working-age adults (18-64 years old) for every person ≥65 years old, will continue to decrease 
by 2060.6 Historically, it has decreased from 6.0 in 1960 to 5.0 in 2000 and ultimately to 4.3 in 
2014. By 2030, the elderly support ratio is expected to dip to 2.8 and to 2.4 by 2060. This 
decrease illustrates declining resources to care for an aging population and highlights the need 
for more resources in primary care.  
EVOLVING PRIMARY CARE IN THE UNITED STATES 
Primary care describes comprehensive healthcare delivery in the outpatient setting and serves as 
a main way that patients access and receive medical care. In fact, it is often the first interaction 
many patients have with the medical system. With focus on overall health and wellness, it is 
essential in maintaining continuity of care. Primary care is an ideal setting to manage most 
chronic disease conditions faced today because of the need for persistent attention and follow-up.  
Primary healthcare delivery in the U.S. is constantly evolving. In particular, team-based care is 
increasingly common given patient health complexities and requirements. Healthcare teams are 
interprofessional and essential in order to alleviate workload from one provider and to deliver 
high-quality health care in today’s demanding society. At the same time, healthcare delivery has 
shifted to value-based care which emphasizes cost savings and quality.7 The Patient Protection 
and Affordable Care Act of 2011 is one example of how the government has responded to 
support this initiative. New reimbursement models issue payment based on pre-determined 
quality metrics, which have spiked growth in patient-centered medical homes (PCMH).8 PCMHs 
emphasize holistic, quality care that is accessible, coordinated, efficient, preventative, and team-
based, involving physicians, nurses, pharmacists, behavioral health specialists, and social 
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workers.9-11 This movement requires healthcare delivery that is efficient and accountable, 
reducing gaps in care.  
In light of these changes and effects on the healthcare system, a declining primary care 
physician supply is particularly challenging. It is estimated that by 2032, the primary care 
physician shortfall range will be between 21,100 and 55,200.12 This expected shortage is driven 
by many factors including the aging and growing U.S. population, physician retirement, and the 
increasing complexity of patients’ health care needs. In fact, about 40% of the entire physician 
workforce is expected to retire in the next decade. This will place significant strain on primary 
care in years to come as we continue to battle complex, progressive chronic diseases such as 
diabetes in an aging population. This only further highlights the importance of primary care 
teams utilizing mid-level healthcare providers, such as pharmacists. Notably, the U.S. Surgeon 
General considers pharmacists to be underutilized and supports their incorporation into primary 
care teams to help improve safety and quality as well as alleviate provider shortage and costs.13  
PHARMACIST UTILIZATION IN PRIMARY CARE 
With time, many advancements in pharmacy practice have occurred and roles of the 
pharmacist have expanded drastically beyond traditional medication dispensing. One example is 
ambulatory care clinical pharmacy, which is a rapidly growing area of specialization today. 
Ambulatory care clinical pharmacy specialists provide direct patient care and are trained in 
chronic disease management, including but not limited to type 2 diabetes (T2DM), hypertension, 
and hyperlipidemia. In 2018, there were >3,800 Board Certified Ambulatory Care Pharmacists 
(BCACPs), which represents a >17% increase from 2017.14 This growth will likely lead to many 
future opportunities for pharmacists to aid in primary care and will thereby increase access to 
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care for patients. In the Veteran’s Affairs (VA) Health System, for example, clinical pharmacists 
reduce primary care provider revisit rates, improve same-day availability, and reduce wait time 
for new patients.15 Clinical roles of ambulatory care pharmacists include medication 
optimization, medication and disease management involving patient assessment and lab 
monitoring, patient education, and quality metric improvement, all of which contribute to 
continuity of care and overall health care efficiency.16  
The role of ambulatory care pharmacists varies by practice site. Pharmacist participation 
in PCMHs, assisting with disease state management and medication therapy management, has 
proven to be beneficial for a variety of disease outcomes including diabetes, hypertension, and 
heart failure.17-25 Much of this is accomplished through collaborative drug therapy management 
(CDTM), which allows for pharmacists to assume a larger role in patient care especially for 
chronic diseases like T2DM.26-28 In different scenarios, pharmacists may be granted independent 
prescribing privileges, such as in the VA Health System, or they may participate in shared 
appointments with the provider where they can make therapeutic recommendations as 
necessary.21,26-28 Others allow for pharmacists to meet with patients independently without 
prescribing privileges; all recommendations must be presented to the provider for approval.21 
Finally, there can be a Collaborative Practice Agreement (CPA), which is a formal relationship 
between the pharmacist and physician that outlines the pharmacist’s roles and responsibilities in 
patient care. Specific responsibilities differ depending on the protocol as defined by the primary 
care physician but often include initiation of new therapy, adjustment of current therapy, and 
ordering of pertinent labs.29 This allows pharmacists to follow-up with patients independently 
and implement care decisions to improve outcomes. This is especially useful in diabetes 
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management as it leads to increased appointments and, therefore, improved access to medical 
care. In three studies, for example, diabetic patients averaged ≥6 office visits with the 
ambulatory pharmacist per year, which allows for timely dose adjustments, appropriate 
monitoring, and patient encouragement.30-32 Through these various new practice models, 
pharmacists can effectively manage T2DM in the outpatient setting; however, patient referral to 
the pharmacist often depends on provider discretion, which may prevent some patients from 
reaping this benefit. It is clear that in today’s healthcare landscape and through various clinical 
structures, pharmacists are an important resource on the medical team who can help manage a 
variety of chronic diseases, including T2DM.  
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Chapter Two: An Integrated Approach to Diabetes Management 
DIABETES AND ASSOCIATED CONCERNS 
Diabetes mellitus, with T2DM accounting for the majority of cases, is a prevalent and 
costly chronic disease in the U.S. Diabetes affects over 30 million people with total annual costs 
estimated at $327 billion in 2017.33,34 Further, estimated costs from both diagnosed and 
undiagnosed diabetes exceed $400 billion, and medical costs for those with diabetes are more 
than twice that for patients without diabetes.34-36  
T2DM is a complex chronic disease that has deleterious effects on multiple bodily 
organs, and is a major cardiovascular mortality risk factor.37-39 Recent data show that even when 
adjusting for other cardiovascular disease risk factors, diabetes alone increases the risk of death 
by 18%.40 Further, the risk of mortality increases proportionally to worsened glucose control as 
demonstrated by higher mortality rates observed at progressive increases in A1C ≥7%. In fact, 
each 1% reduction in the A1C value can reduce the risk of microvascular complications by 37% 
and the risk of mortality by 21% without any observed limit of glycemia to provide benefit.41 
This proves that the A1C value is an important marker of clinical response when managing 
T2DM and that percentage decreases are significant regardless of baseline A1C values. As a 
cause of death, diabetes itself is often underreported and likely represents a contributing cause of 
death in most cases, yet it still remains the seventh leading cause of death in the U.S.42,43 With 
the projected primary care physician shortfall and heightened healthcare burden, T2DM will 
continue to place a large strain on the healthcare system in the U.S. Therefore, comprehensive 
diabetes management, utilizing team members such as pharmacists, is essential in order to 
address system-wide challenges imposed by this disease and to improve patient health and 
mitigate complications. 
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PHARMACIST-MANAGED DIABETES CARE 
Diabetes management is complex and time-consuming, requiring persistence from both 
the patient and healthcare provider. Increased complexity is illustrated by more than seven drug 
classes available to treat T2DM and the numerous complications of uncontrolled T2DM 
affecting several bodily systems, including but not limited to neurological, renal, and 
cardiovascular systems.34,44-46 Difficulty reaching therapeutic goals can be attributed to factors 
such as complex therapies, poor medication adherence, concerning side effects, and financial 
burdens.47,48 With medication therapy as the hallmark in diabetes treatment after lifestyle 
modification, ambulatory care clinical pharmacists are well-trained to assist in appropriate 
therapy selection and to address drug-related concerns.  
The Asheville Project in 1996 first demonstrated the positive effects pharmacists can 
have on diabetes outcomes when integrated into healthcare teams.49 The pharmacists involved in 
this study provided cognitive services for patients including glucometer training, general diabetes 
education, and clinical assessment. Improvements in A1C, total cholesterol, and low-density 
lipoprotein (LDL) were shown over 14 months as well as decreased costs by $472 per patient per 
year. For example, at each follow-up the percentage of patients who improved or lowered the 
A1C was more than 50%, demonstrating persistent positive effects of pharmacists over time. In 
addition, pharmacists improve standards of diabetes care, as recommended by the American 
Diabetes Association, compared to usual care including timely A1C measurement (91.2% vs. 
76.7%; P=0.0013), lipid measurement (95.6% vs. 70.0%; P<0.0001), microalbumin screening 
(75.2% vs. 15.7%; P<0.0001), foot exams (87.6% vs. 47.6%; P<0.0001), and pneumococcal 
(80.5% vs. 37.6%; P<0.0001) and influenza vaccines (74.3 vs. 50.0%; P<0.0001).50 Meeting 
these standards are critical in maintaining the overall health of the diabetic patient. A recent 
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meta-analysis, including ≥7000 patients ≥18 years old with type 1 or 2 diabetes, assessed the 
impact of pharmacists on diabetes outcomes in ambulatory settings. Compared to usual care, 
pharmacists lowered the A1C from baseline by 1.1% (95% CI, 0.88-1.27) with an overall 
standardized mean difference of 0.56 (P<0.001), indicating a significant and moderate effect.21 
Significant reductions were demonstrated across age groups and baseline A1C values. 
Pharmacists also improved cardiovascular disease risk factors in these patients. In the same 
study, pharmacist interventions reduced LDL cholesterol [-10.6 mg/dL (95% CI, -7.1 to -14.1)] 
and systolic blood pressure values (SBP) [SBP -4.3 mm Hg (95% CI, -4.3 to -6.2)] with 
differences compared to usual care. A second systematic review and meta-analysis including 15 
randomized controlled trials with >9,000 patients showed that pharmacists practicing 
independently or in conjunction with other medical professionals led to significant reductions in 
risk factors compared to usual care, including SBP (-6.2 mm Hg [95% CI, -7.8 to -4.6]), diastolic 
blood pressure (DBP) (-4.5 mm Hg [95% CI, -6.2 to -2.8]), and LDL cholesterol (-11.7 mg/dL 
[95% CI, -15.8 to -7.6 mg/dL]).51 Further, pharmacists have also shown to be cost-effective for 
disease management including diabetes and hypertension, with benefit-to-cost ratios ranging 
from 1:1 to 8.5:1 for diabetes.52,53 In the VA Health System, for example, pharmacist visits cost 
about $15,000 less compared to primary care physician visits per 1,000 30-minute encounters.15 
These data provide evidence that pharmacists can improve diabetes outcomes and help achieve 
standards of care while mitigating costs, and support their inclusion and importance on the 
medical team.  
Currently, most clinical pharmacists see patients based on a physician referral system; 
however, it is unclear which patients are most likely to benefit from these services. In 2017, Lam 
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and colleagues evaluated predictors of response to pharmacist involvement in diabetes 
management.54 This was a retrospective cohort study including three treatment facilities in a 
united health system in Cleveland, Ohio. The pharmacists providing care operated under a CPA 
allowing for independent patient visits and prescribing privileges within the scope of practice. 
Included patients were >18 years old and had an A1C ≥9% at baseline. Response to the clinical 
pharmacist was defined as a decrease in the A1C by ≥2% or achieving an A1C <8% one year 
after the first visit. Failing to respond to these A1C goals or loss to follow-up qualified as a non-
responder in the study. The authors found a history of cerebrovascular accident (CVA) (AOR 
2.7; 95% CI, 1.2-5.9), bolus insulin at baseline (AOR 0.5; 95% CI, 0.4-0.8), and baseline A1C 
(AOR 1.2; 95% CI, 1.1-1.3) to be independently predictive of response. CVA and baseline A1C 
were positive predictors of response, whereas bolus insulin at baseline was associated with 
therapeutic failure. This study had a meaningful and clinically significant definition of success. 
While this was the first study to specifically assess predictors of response to pharmacist-managed 
diabetes care, it did not assess interventions made during the study period and only assessed 
baseline patient demographics and clinical data. Additionally, sodium-glucose cotransporter-2 
(SGLT-2) inhibitors were absent from this study due to timing of Food and Drug Administration 
(FDA) approval. Lastly, the study endpoint was one year after the initial pharmacist visit and 
included patients even if they only had a single visit, providing potentially weak association to 
the pharmacist interventions one year prior to the study outcome. While helpful to address this 
research question, additional studies are needed to provide more conclusive evidence in order to 
better identify patients and interventions associated with therapeutic response. 
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Chapter Three: Objectives and Hypotheses 
KNOWLEDGE GAP 
There is a lack of standardization or guidance in referring patients to the clinical 
pharmacist for T2DM management, which likely results in patients missing out on this beneficial 
service. Predictive analytics are useful to help inform health organizations which patients should 
be targeted for higher levels of care in order to improve healthcare efficiency. Specifically, it 
would be useful to know which patients and which specific clinical interventions are most likely 
to demonstrate benefit from pharmacy services. In doing so, this can help increase the number of 
physician referrals, expand access to care, and ultimately, improve patient outcomes.  
To our knowledge, only one study has assessed patient predictors of response to diabetes 
care provided by a clinical pharmacist.54 Our study will build on this research by assessing both 
baseline patient characteristics and clinical interventions made in a diverse population. This will 
allow for a more thorough approach to determining variables implicated in clinical response. It 
will also be a reflection of medications currently used in practice to treat T2DM, including 
SGLT-2 inhibitors. The study findings can help influence protocols for physician referral to the 
clinical pharmacist for T2DM management, reaching patients most likely to benefit who may 
otherwise have no exposure to this service. Further, this study will help identify specific clinical 
interventions that are associated with response in our patient population. Thus, the goals of this 
study are to identify predictors of response to pharmacist-led diabetes care in order to better 
identify high-risk patients who would benefit from referral to the clinical pharmacist and to 
elucidate specific interventions that provide most benefit. 
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OBJECTIVE 1 
Describe clinical responses to pharmacist-led diabetes care. 
HYPOTHESIS 1 
Responders, based on study definitions, will represent about 45% of the patient population 
in this study. 
OBJECTIVE 2 
Identify patient characteristic and interventional variables that are predictive of clinical 
response to pharmacist-led diabetes care. 
HYPOTHESIS 2 
 Higher baseline A1C, a lack of bolus insulin at baseline, and assistance with financial 
barriers will be positive predictors of therapeutic response. 
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Chapter Four: Methods 
STUDY SETTING AND DESIGN 
This study analyzed patients referred to an ambulatory care clinical pharmacist for 
evaluation and management of T2DM in San Antonio, Texas. The two pharmacists providing 
care during the study period had Doctor of Pharmacy degrees as well as residency training and 
board certification in ambulatory care. Study sites included The University of Texas Health 
Medical Arts and Research Center Primary Care Center, The University of Texas Health Medical 
Drive Primary Care Center, and the University Health System Robert B. Green Family Medicine 
Clinic. All three study sites had established CPAs in place between the pharmacist and primary 
care physicians, which allowed the pharmacist to meet independently with patients, evaluate 
treatment, and make therapeutic adjustments and schedule follow-up appointments as necessary.  
This study was a retrospective cohort study. Patients were eligible if they were ≥18 years 
old at time of referral and had a referral to the pharmacist for T2DM management. Included 
patients had at least one completed visit with the pharmacist between January 1, 2015 and 
December 31, 2018. We excluded patients diagnosed with gestational diabetes or type 1 diabetes, 
a visit with an endocrinologist during the study period, a baseline A1C <7%, or an absent A1C 
value at baseline or at follow-up. We also excluded patients who previously sought care from the 
pharmacist before the study period and were subsequently referred again to the pharmacist. If 
patients had a consult order placed but no completed initial visit with the pharmacist, they were 
excluded. Clinical response was defined as a reduction in the A1C value by ≥1% from baseline 
or meeting the documented A1C goal between 3 and 6 months from the baseline A1C value. 
Non-responders were defined as failing to meet these A1C goals. 
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DATA COLLECTION AND ANALYSIS 
We gathered data from the Sunrise electronic health record for University Health System 
and EPIC for University of Texas Health clinics. Patients were identified by having a physician 
consult order in place to the clinical pharmacist. Data were extracted at baseline, during the study 
period (per subject – the 6 months following the first visit with the pharmacist), and at the end of 
the study (Figure 1). Baseline variables were collected up to one year prior to the first visit with 
the pharmacist. Medical record numbers were stored in a protected study key and were 
reassigned to a new study code number. Only the primary investigator had access to the study 
key and only one copy of the key existed. We stored our collected data in Research Electronic 
Data Capture (REDCap).55 Variables included demographics (age, sex, ethnicity), weight, body 
mass index (BMI), preferred language, smoking status, employment, comorbidities, vital signs, 
laboratory values, duration of diabetes, clinic location, number of visits completed with 
pharmacist, number of visits completed with primary care physician or provider, pharmacist 
interventions, and medical therapy (Table 1). We also collected insurance type including public, 
private, or none (i.e., self-pay). Specific to Bexar County, Texas, CareLink enrollment was 
captured as well. CareLink is not an insurance program but instead is a patient assistance 
program funded by the county that provides significant financial assistance for medical care to 
patients in need; patients can often receive prescription medications for copays as low as $0 
depending on certain criteria. CareLink is not available for people with public or private 
insurance or people living outside of Bexar County.  
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Figure 1. Study Timeline 
 
Table 1. Definitions and Timeframes for Collected Variables 
Variable Name Definition*  




Scheduled medications listed on patient’s outpatient medication list 
including scheduled prescription and over-the-counter medications (does 








Comorbidities in the Charlson Comorbidity Index56 which include: 
-Hypertension 
-Hyperlipidemia 
-History of myocardial infarction 
-History of cerebrovascular accident  
-Congestive heart failure 
-Liver disease 
-Retinopathy 
-Nephropathy or chronic kidney disease 
-Neuropathy 
-Dementia 
-Chronic obstructive pulmonary disease 
-Cancer or any malignancy 
-HIV/AIDS 
Blood pressure Blood pressure measured in mm Hg  
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Table 1. Definitions and Timeframes for Collected Variables, Cont. 
Microalbuminuria Presence or absence of microalbuminuria (30-299 mg/g creatinine in 
urine) 
Serum creatinine Serum creatinine laboratory value (mg/dL)  
eGFR eGFR laboratory value (mL/min/1.73m2)  
AST AST laboratory value (Units/L)  
ALT ALT laboratory value (Units/L)  
LDL cholesterol LDL laboratory value (mg/dL)  
HDL cholesterol HDL laboratory value (mg/dL)  
Total cholesterol  Total cholesterol laboratory value (mg/dL)  
TG TG laboratory value (mg/dL)  
Abbreviations: T2DM, Type 2 Diabetes Mellitus; HIV, Human Immunodeficiency Virus; AIDS, 
Acquired Immune Deficiency Syndrome; eGFR, estimated glomerular filtration rate; AST, 
aspartate aminotransferase; ALT, alanine aminotransferase; LDL, low-density lipoprotein; HDL, 
high-density lipoprotein; TG, triglycerides 
*Data were collected either at baseline (first visit with pharmacist) or at the time point closest to 
baseline and up to one year prior to the first visit 
 
Pharmacist interventions for diabetes care were gathered from recorded information in 
patient encounter notes. These included actions such as starting or discontinuing a medicine, 
adjusting a dose, and providing self-monitored blood glucose counseling. It also included referral 
to resources including a dietician or a community-based twelve-step program called Overeaters 
Anonymous. Of note, medication optimization in this study refers to a reduction in the number of 
times per day a patient takes medications. For example, if a patient takes medications three times 
per day and this can be further simplified to once or twice per day, this intervention would be 
recorded as medication optimization.  
Descriptive analyses were conducted on all collected variables. Nominal data were 
analyzed between responders and non-responders using either the chi-square or Fisher’s exact 
test as appropriate. Ordinal and continuous data were analyzed using either the Wilcoxon rank 
sum or Student t-test as appropriate. A p-value of <0.05 was considered significant on bivariable 
analysis. Multivariable logistic regression analyses were conducted on collected covariates 
 16 
demonstrating a p-value <0.20 on bivariable analysis in order to determine significant predictors 
of response. Variables meeting a threshold of p<0.05 in the logistic regression model were 
considered independent predictors of response. We utilized JMP software (JMP Pro Version 
14.0.0) for data analysis. Sample size was determined based on a two sample proportions 
calculation. Based on previous literature, we estimated that 45% of patients will be considered 
“responders” to pharmacy interventions.54 We also predicted that a clinically significant 
difference for any one covariate to be a 20% difference between a responder and non-responder. 
Given this information with an alpha of 0.05 and power of 80%, 178 patients were required to 
detect a 20% difference between responders and non-responders for any given covariate.  
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Chapter Five: Results 
 The total number of referrals made to the pharmacists during the study period was 1,216 
among the three clinic sites. The primary investigator screened 700 patient records and 
ultimately excluded 520 (Figure 2). Table 2 describes the common reasons for study exclusion 
among patients with a T2DM referral. Of these referrals, 180 patients met inclusion criteria and 
were included in this study. Patients were predominantly English-speaking, obese, Hispanic 
females (Table 3). Most patients had metformin treatment at baseline and the end of the study. 
Concomitant chronic diseases, including hypertension and hyperlipidemia, were prevalent.  
 
Figure 2. Patient flowchart. 
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Table 2. Reasons for Study Exclusion 
Reason for Study Exclusion Number of Excluded Patients 
(n=279) 
Absent baseline A1C 22 
Baseline A1C <7% 17 
Absent follow-up A1C 38 
First visit outside study timeframe 82 
Consultation with endocrinology 10 
First visit not completed 110 
 
Table 3. Characteristics of Study Cohort 
Characteristic Overall  
(n = 180) 
Responders 
(n = 119) 
Non-
Responders 
(n = 61) 
P-
value 
Age (years) 56 ± 11 55 ± 11 57 ± 10 0.119 
Weight (kg) 90 (74-103) 90 (74-105) 92 (74.5-100) 0.749 
BMI (kg/m2) 33 (28.7-38.2) 32.4 (28.3-38.3) 33.3 (29.5-38.3) 0.637 
Obesity (BMI ≥30) 126 (70) 81 (68.07) 45 (73.77) 0.426 
Male 67 (37.2) 44 (36.97) 23 (37.70) 0.924 
Ethnicity 










   English 
   Spanish 















   UT  












   Yes 












   Public 
   Private 














CareLink 37 (21) 23 (19) 14 (23) 0.572 
Past or Current Smoker 64 (36) 40 (34) 24 (39) 0.449 
Baseline SBP 129.5 (119-
143) 
128 (119-140) 133 (120.5-147) 0.083 
Baseline DBP 72.3 ± 10.3 72.82 ± 9.71 71.36 ± 11.29  0.805 
Duration of Diabetes 










Table 3. Characteristics of Study Cohort, Cont. 
Baseline A1C 9.9 (8.5-11.2) 10.1 (8.9-12.2) 9.0 (8.45-10.5) 0.003 
Microalbuminuria 81 (50) 53 (50) 28 (51) 0.913 
eGFR >60 mL/min/1.73m2 137 (78) 92 (79) 45 (75) 0.517 
SCr 0.85 (0.7-1.08) 0.87 (0.71-1.07) 0.81 (0.67-1.09) 0.602 
AST 20 (15-31) 20 (16-34) 20 (15-25) 0.137 
ALT 28 (20-41) 29 (20-44) 26 (20-35) 0.168 
LDL 92 (62-125) 92 (61.5-118.5) 91 (66-131) 0.876 
HDL 43 (36-53) 42 (36-52) 44 (36-54) 0.283 
Total Cholesterol 172 (134-205) 171 (131-205) 172 (135-224) 0.712 
Triglycerides 159 (108-262) 164 (114-263) 147 (92-254) 0.139 
Comorbidities 
   Hypertension 
   Hyperlipidemia 
   MI 
   CVA 
   CHF 
   Liver Disease 
   Retinopathy 
   Nephropathy or CKD 
   Neuropathy 
   Dementia 
   COPD 
   Cancer or Malignancy 
   HIV/AIDS 





























































Number of Comorbidities 3 (2-4) 3 (2-4) 3 (2-4) 0.083 
Hospital or ER admission at 
baseline 50 (28) 30 (25) 20 (33) 0.286 
Hospital or ER admission 
during follow-up 26 (14) 14 (12) 12 (20) 0.161 
Anti-Diabetic Medications at 
Baseline 
   Metformin 
   TZD 
   SGLT-2 Inhibitor 
   GLP-1 Receptor Agonist 
   DPP-4 Inhibitor 
   Sulfonylurea 
   Meglitinide 
   Basal insulin 
   Bolus insulin 



















































Table 3. Characteristics of Study Cohort, Cont. 
Insulin at Baseline 104 (58) 68 (57) 36 (59) 0.809 
Injectable at Baseline 110 (61) 70 (59) 40 (66) 0.377 
Number of Anti-Diabetic 
Medications at Baseline 2 (2-3) 2 (2-3) 2 (2-3) 0.234 
Notable Baseline Medications  
   Antipsychotic 
   Oral corticosteroids 
   Lithium 
   Hormone Replacement 

























Number of Baseline 
Medications 7 (5-10) 7 (5-10) 7 (6-10) 0.681 
Anti-Diabetic Medications at 
End of Study 
   Metformin 
   TZD 
   SGLT-2 Inhibitor 
   GLP-1 Receptor Agonist 
   DPP-4 Inhibitor 
   Sulfonylurea 
   Meglitinide 
   Basal insulin 
   Bolus insulin 

















































Insulin at End of Study 121 (67) 77 (65) 44 (72) 0.312 
Injectable at End of Study 136 (76) 88 (74) 48 (79) 0.480 
Number of Anti-Diabetic 
Medications at End of Study 
3 (2-4) 3 (2-4) 3 (2-4) 0.728 
Abbreviations: BMI, body mass index; UT, University of Texas; UHS, University Health 
System; SBP, systolic blood pressure; DBP, diastolic blood pressure; A1C, hemoglobin A1c; 
eGFR, estimated glomerular filtration rate; SCr, serum creatinine; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase; LDL, low-density lipoprotein; HDL, high-
density lipoprotein; MI, myocardial infarction; CVA, cerebrovascular accident; CHF, congestive 
heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HIV, 
human immunodeficiency disease; AIDS, acquired immunodeficiency syndrome; IQR, 
interquartile range; ER, emergency room; TZD, thiazolidinedione; SGLT-2, sodium-glucose co-
transport-2; GLP-1, glucagon-like peptide 1; DPP-4, dipeptidyl peptidase-4 
All data are represented as n (%) unless stated otherwise. 
Age and diastolic blood pressure are represented as mean ± standard deviation. All other listed 
continuous variables are represented as median (IQR). 
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Altogether, 119 patients (66%) were considered responders to clinical pharmacist 
interventions for diabetes care. Of the responders, 110 patients (92%) had a decrease in the A1C 
value by ≥1% and 9 patients (8%) met their documented goal without this threshold change in 
A1C. Fifty-one patients reached their documented A1C goal during the study. The median (IQR) 
change in A1C from baseline for responders and non-responders was -2.2% (-3.7 to -1.3) and 
0.4% (-0.4 to 1.05) (P<0.001), respectively. The most common types of interventions were 
starting a new medication, making a dose adjustment, discontinuing a medication, and providing 
a blood glucose log in 73%, 57%, 48%, and 37% of patients, respectively. Responders and non-
responders did not differ significantly based on age, gender, ethnicity, preferred language, 
weight, insurance type, smoking status, or comorbidity type except for retinopathy. Non-
responders were more likely to have retinopathy at baseline compared to responders (24.6% vs. 
11.8%, P=0.030). Lab values were similar between groups except for baseline A1C, which was 
significantly elevated for responders (10.1% vs. 9.0%, P=0.0026) (Table 3). Overall utilization 
rates of insulin and sulfonylureas decreased in the study cohort from baseline to end of study 
(Figure 3). Metformin use was more common among responders at both baseline (76.5% vs. 
62.3%, P=0.048) and end of study (83.2% vs. 67.2%, P=0.017) compared to non-responders. 
Further, bolus insulin use at baseline was more common among non-responders (41% vs. 20.2%, 
P=0.004). The only recorded pharmacist intervention that was significantly different between 
groups was medication optimization among responders compared to non-responders (11.8% vs. 
1.6%, P=0.009) (Table 4). Lastly, responders demonstrated a significantly different median 
number of completed visits with the pharmacist (2 (1-3) vs. 2 (1-2), P=0.0217), and the mean 
number of visits between these groups were 2.4 and 1.96 (P<0.006), respectively. 
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Figure 3. Medication Changes in Overall Cohort at Baseline and End of Study 
 
 
Table 4. Baseline and Interventional Diabetes Care. 
Measure Overall  
(n = 180) 
Responders 
(n = 119) 
Non-
Responders 
(n = 61) 
P-
value 
Number of Completed Visits with 
Pharmacist 2 (1-3) 2 (1-3) 2 (1-2) 0.022 
Number of Completed Visits with PCP 2 (1-3) 1 (0-2) 2 (1-3) 0.121 
Pharmacist Interventions 
   Started New Medication 
   Dose Adjustment 
   Discontinued Medication 
   Provided BG log and SMBG 
Counseling 
   Referral to Dietician 
   Referral to OA 
   Assistance with Financial Barriers 
   Provided Pillbox 
   Medication Optimization 


















































Abbreviations: PCP, primary care provider; BG, blood glucose; SMBG; self-monitored blood 
glucose; OA, overeaters anonymous 
All listed nominal variables are represented as n (%) unless stated otherwise.  








































 Twenty-five variables were included in the multivariable logistic regression analysis in 
order to determine predictors of response to the clinical pharmacist as shown in Table 5. 
Significant predictors included baseline A1C (OR 1.41; 95% CI 1.08-1.85), number of 
completed visits with both the primary care provider (OR 0.69; 95% CI 0.49-0.96) and the 
pharmacist (OR 1.65; 95% CI 1.03-2.64), and medication optimization (OR 10.68; 95% CI 1.04-
109.9). All mentioned significant variables, except for number of completed visits with the PCP, 
were positive predictors of response. All other variables inputted into the logistic regression 
model were not associated with response in the primary outcome. 
Table 5. Multivariable Logistic Regression Model for Predictors of Response 
Characteristic Odds Ratio 95% CI P-value 
Sulfonylurea at baseline 0.33 0.10-1.02 0.055 
Bolus insulin at baseline 0.24 0.06-1.02 0.053 
Baseline A1C (per percentage point >7%) 1.41 1.08-1.85 0.013 
Completed visits with pharmacist (per additional visit) 1.65 1.03-2.64 0.037 
Completed visits with PCP (per additional visit) 0.69 0.49-0.96 0.029 
Medication optimization 10.68 1.04-109.9 0.046 
Age (per additional year) 1.02 0.97-1.08 0.337 
Number of comorbidities (per additional comorbidity) 1.00 0.63-1.60 0.987 
Baseline SBP (per additional mm Hg) 1.00 0.97-1.03 0.962 
AST (per additional unit) 1.03 0.97-1.10 0.290 
ALT (per additional unit) 0.99 0.96-1.03 0.641 
Triglycerides (per additional unit) 1.00 1.00-1.00 0.818 
Clinic location (UT vs. UHS) 0.72 0.25-2.05 0.538 
DM duration (<10 vs. ≥10 years) 1.52 0.52-4.46 0.446 
Hypertension 0.66 0.14-3.11 0.594 
Retinopathy 0.73 0.17-3.20 0.675 
Hospital admission during follow-up 0.61 0.18-2.07 0.431 
Metformin at baseline 0.89 0.22-3.54 0.864 
Hormonal replacement at baseline 0.27 0.02-4.26 0.351 
Metformin at end of study 2.08 0.49-8.86 0.320 
Bolus insulin at end of study 1.52 0.35-6.60 0.578 
Dose change 1.18 0.43-3.22 0.749 
BG log and SMBG counseling 1.36 0.50-3.72 0.549 
Referral to dietician 1.99 0.30-13.31 0.477 
Ethnicity (non-Hispanic vs. Hispanic) 1.62 0.60-4.36 0.339 
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Chapter Six:  Discussion 
This retrospective cohort study involving patients seeking care for T2DM by a clinical 
pharmacist in two different health systems in San Antonio, Texas demonstrates not only the 
effectiveness of this clinical service, but also specific characteristics and interventions that predict 
therapeutic response. Nearly two of every three patients were considered responders in this study, 
demonstrating a higher response rate than shown previously.54 Further, the median change in A1C 
from baseline amongst responders was -2.2%, which is considerable and clinically significant 
especially given a short six month maximum follow-up. These results demonstrate the 
effectiveness of our ambulatory clinical pharmacy services for T2DM management. We 
discovered that higher baseline A1C, more visits with the pharmacist, fewer visits with the PCP, 
and medication optimization were all independently predictive of clinical response.  
Clinical pharmacists have been involved in chronic disease management, specifically 
T2DM, for many years, but is not clear exactly which patients benefit most or which interventions 
are most effective. Similar to the study by Lam, et al., a higher baseline A1C was predictive of 
response in our study; however, their study did not assess clinical interventions made. Higher 
baseline A1C values have consistently been shown to predict a larger decrease in A1C compared 
to lower baseline A1C and elicit increased effectiveness of anti-diabetic medications.57-61 
Interestingly, bolus insulin at baseline was not statistically significant as in the previous study but 
trended towards significance as a predictor of non-response in our study. Perhaps a larger sample 
size would result in statistical significance. With many other therapeutic options recommended by 
guidelines prior to bolus insulin, its use may be representative of exhausted medication trials, 
progression of clinical disease, or a last resort.45 Requirement of bolus insulin may also indicate 
higher levels of insulin resistance and progression of disease. Lastly, bolus insulin often requires 
multiple injections per day, which is likely to limit adherence to therapy and ultimately reduce 
therapeutic benefit. Similarly, sulfonylurea use at baseline was not a statistically significant 
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predictor of response but trended towards significance. Their use was notably reduced for all 
patients at the end of study compared to baseline. The unfavorable use of sulfonylureas can be 
attributed to their reduced effectiveness over time and negative adverse effects.62 These agents act 
directly on pancreatic beta cells, placing them under additional strain and ultimately catalyzing 
their dysfunction. Unlike the study by Lam, et al., we did not find a history of CVA to be a predictor 
of response. In fact, no specific comorbidities were associated with response or non-response in 
the logistic regression model even though retinopathy was significantly increased amongst non-
responders on bivariate analysis.  
Analyzing the medication classes between responders and non-responders from baseline 
compared to end of study provides useful information as well. First, metformin use was 
significantly elevated amongst responders at both baseline and end of study; however, it was not 
independently predictive of response. Nevertheless, this highlights the first-line use of metformin 
for all patients as appropriate given its affordability, high efficacy, and established safety. 
Medication classes considered second-line including SGLT-2 inhibitors, GLP-1 receptor agonists, 
and TZDs are all numerically increased at end of study compared to baseline for the overall cohort. 
This demonstrates the pharmacist’s efforts to add appropriate guideline-recommended 
medications in order to achieve clinical response.  
Increased number of visits with the pharmacist was predictive of clinical response. While 
the median number of visits did not numerically differ between groups, the mean was slightly 
elevated in the responder group. This indicates that while specific interventions may not 
demonstrate benefit in our study, the education received and interactions with a pharmacist are 
therapeutically beneficial. The one recordable pharmacist intervention associated with clinical 
response was medication optimization. Complex medication regimens with multiple dosing times 
per day can contribute to medication nonadherence. Pharmacists in the study utilized medication 
optimization in order to ensure treatment adherence and convenience. This demonstrates the 
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importance and critical role of pharmacists with detailed knowledge and attention regarding 
medication dosing and interactions. This intervention should be emphasized at all patient visits. 
Interestingly, more visits with the PCP was a negative predictor of response in this study. While 
the explanation for this finding is unclear, it may reflect acute concerns needing to be addressed 
during the study, which could hinder the time and attention spent on T2DM management. In 
addition to showing positive effects on A1C levels, pharmacists can also reduce gaps in care and 
help achieve quality standards.25 Many of these interventions and effects were not measured or 
reported in this study.  
There are several strengths to this study. First, the results provide real world data involving 
all anti-diabetic medication classes currently available. Further, this study involves patients with a 
broad range of socioeconomic statuses from two health systems increasing its generalizability. The 
relatively short follow-up time more strongly reflects the effect of pharmacist interventions 
compared to studies with longer follow-up, especially if patients only complete one visit. This 
ultimately strengthens the conclusions of the study. Lastly, this study considered both baseline and 
interventional data in order to predict therapeutic response, providing a comprehensive 
interpretation of patient care and study results. 
This study also has potential limitations. First, it is limited due to its retrospective nature, 
which is prone to missing data, inaccurate data reporting, and misclassification bias. For example, 
an intervention may have occurred but was not explicitly recorded in the patient’s clinical note and 
would, therefore, not be considered. In addition, due to the nature of the study, certain clinical 
interventions made may not be recordable and consequently cannot be included in the analyses. 
For example, while referral to a dietician can be recorded, specific dietary recommendations made 
by the pharmacist were not recorded. It is expected that dietary recommendations, which are 
essential in diabetes treatment, are made at each visit; however, the extent of these 
recommendations are not easily quantified into recordable research data. Further, since patients 
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are referred to the clinical pharmacist based on provider discretion, this could lead to selection 
bias; each referring physician may create a consultation referral based on different factors, which 
may influence the results to an unknown extent. Our findings may have limited generalizability to 
the U.S.  population given its high rate of Hispanic ethnicity of 58%. Importantly, ethnic 




Chapter Seven:  Conclusion and Future Directions 
This study demonstrates the effectiveness of ambulatory clinical pharmacists in T2DM 
management and sheds light on specific patient characteristics and clinical interventions that help 
predict therapeutic response. Nearly two-thirds of patients were considered responders in this 
study, which is greater than shown in previous studies. We found that higher baseline A1C, more 
visits with the pharmacist, fewer visits with the PCP, and medication optimization were all 
associated with clinical response. These findings can be used to influence the development of 
referral protocols to clinical pharmacists for diabetes management and reinforce the importance of 
interventions such as medication optimization. Innovative services that can incorporate medication 
optimization, such as pill box filling, could be offered to patients in the future. Here, pharmacists 
can assist patients in need by optimizing medication regimens, providing education, and 
reinforcing medication adherence. New pharmacist referral protocols that automatically refer or 
suggest referral for patients with A1C ≥10% could assist in reaching more patients who may 
otherwise miss out on this beneficial service. With the increasing healthcare burden in the U.S., 
primary care will only continue to benefit from clinical pharmacist involvement on healthcare 
teams. Clinical pharmacists demonstrate clear effectiveness on diabetes outcomes and should be 
involved in its management when possible. This study supports the continued inclusion of 
pharmacists on primary healthcare teams, specifically for T2DM management, and further large-
scale studies are needed to validate these results. Lastly, future studies should incorporate cost 
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